US races to regulate AI and crypto—while therapy bots and “Clarity” collide with Wall Street

On September 14, 2026, a cluster of US policy and market signals converged around artificial intelligence governance and crypto regulation. Sen. Kennedy is preparing an AI “kill switch” bill, framing the issue as system-level control and safety for AI-enabled operations. At the same time, the Trump administration is rolling out AI agents that provide therapy and can prescribe medicine, triggering concerns about patient safety and the role of venture capital in shaping deployment. In parallel, the crypto policy debate sharpened: the SEC’s chair, Mark Atkins, backed the Clarity Act but said the agency would continue pushing crypto rules even if the legislation fails, focusing on crypto issuance, transfer agent modernization, and custody. Strategically, the US is attempting to set the rules of the road for two fast-moving domains where private platforms and financial incumbents are moving faster than regulators. The “kill switch” concept suggests a willingness to impose hard constraints on AI systems, potentially shifting leverage toward government oversight and away from model developers and integrators. Meanwhile, the Clarity Act discussion reflects a regulatory tug-of-war between creating a clearer framework for banks and brokers and the reality that firms have already integrated digital assets into core workflows. Who benefits is split: compliance-oriented institutions and regulated custodians gain optionality if clarity arrives, while venture-backed AI deployers face higher scrutiny if safety failures or liability disputes emerge. The political economy angle is acute—AI productization and crypto market infrastructure are both becoming policy battlegrounds, with influence contests between regulators, financial firms, and capital providers. Market implications are likely to concentrate in financial services technology, custody and compliance tooling, and AI-enabled advisory platforms. The Clarity Act narrative can affect expectations for crypto issuance and custody economics, influencing risk premia for regulated crypto infrastructure and the adoption curve for banks, brokers, and asset managers; however, the articles suggest failure would slow adoption rather than halt it. Separately, Anthropic is pitching a Claude version for financial advisers that blends the chatbot with financial analytics and risk management technology run by major asset managers, including BlackRock and Vanguard, signaling demand for “AI + compliance + portfolio risk” stacks. If therapy-and-prescription agents expand, healthcare-adjacent AI vendors and insurers may face new liability and monitoring costs, which can translate into higher compliance spend and potentially slower procurement cycles. In instruments terms, the immediate read-through is more about sector sentiment—regulatory headline risk for crypto intermediaries and AI health-tech—than about a single commodity or FX move. What to watch next is whether US lawmakers and regulators translate these signals into enforceable standards and timelines. For AI, the key trigger is the progression of Sen. Kennedy’s “kill switch” bill: committee movement, draft language on system shutdown authority, and any carve-outs for medical use will determine how quickly deployment risk rises. For crypto, monitor SEC rulemaking milestones tied to issuance, transfer agent modernization, and custody, because Atkins indicated the agency will proceed regardless of Clarity’s fate. On the market side, watch Anthropic’s enterprise traction with adviser platforms and whether major asset managers expand integrations beyond pilots, as this can accelerate demand for regulated AI governance features. Finally, track any safety incidents or enforcement actions connected to therapy and prescription AI agents, since even a single adverse event could force rapid policy tightening and reshape adoption expectations across both AI and digital-asset ecosystems.

Geopolitical Implications

• 01

  The US is shaping de facto global standards for AI safety and financial-technology governance, influencing cross-border adoption by multinational firms.

• 02

  Regulatory leverage is shifting toward institutions that can operationalize compliance (custody, transfer agents, risk management), potentially consolidating power among large incumbents.

• 03

  The combination of medical AI deployment and venture capital influence may become a template for future governance battles, affecting authorization timelines elsewhere.

Key Signals

• —Committee movement and draft language for the AI “kill switch” bill, especially scope and medical carve-outs.
• —SEC rulemaking milestones on crypto issuance, transfer agent modernization, and custody regardless of Clarity’s outcome.
• —Any safety incidents or enforcement actions tied to AI therapy and medicine-prescribing agents.
• —Enterprise adoption metrics for Anthropic’s Claude adviser tooling and expansion beyond pilots.